Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease Ferreri and Prilenia Therapeutics B.V. announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington’s disease (HD) has received authorization…
CooperSurgical Announces the Donation of More Than 300 Cord Blood Samples and Additional Funding to Support Ongoing Stem Cell Research at the University of Toronto CooperSurgical Affiliate donates hundreds of cord blood units and additional funding to advance stem cell…
EmeraNova™ Adds Hyaluronic Acid Matrix Technology, Supporting Expansion to New Care Settings EmeraNovaTM, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, is expanding its tissue preparation and restorative capabilities through…
Cofactor Genomics Publishes OncoPrism-NSCLC Clinical Validation, Advancing Lung Cancer Immunotherapy Diagnostics Beyond PD-L1 Cofactor Genomics announced publication of its OncoPrism®-NSCLC clinical validation study in npj Precision Oncology, a peer-reviewed Nature Portfolio journal. The study represents the latest results from Cofactor’s…
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting Organon a global healthcare company with a mission…
Sea Dragon Energy Celebrates First-Fuel Milestone, Dedicates Hawai’i R&D Facility Sea Dragon Energy, Inc. celebrated a major milestone in its mission to transform seawater into strategic aviation fuel, marking the production of its first synthetic fuel and the ceremonial dedication…
TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent TwinStrand Biosciences the pioneer in Duplex Sequencing® technology, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB)…
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis TG Therapeutics, Inc. announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression…
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION-1 trial…
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies, Inc. a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of…
DIC Commences Global Rollout of ECOVART™, a Low Solvent–Content Gravure Ink that Helps Improve Productivity DIC Corporation announced that it will commence the global rollout of gravure ink ECOVART™, which requires the addition of significantly less solvent than conventional gravure…
New Real-World Data for Miach Orthopaedics’ BEAR® Implant Demonstrate Low Retear Rates and Clinically Meaningful Improvements Following ACL Restoration Miach Orthopaedics, Inc., developer of the BEAR® Implant for anterior cruciate ligament (ACL) restoration, announced publication of new two-year results from…